GlassScriptPhysician profile
Brian Anthony White
NPI 1003574765
$7,889.15
in general payments reported to CMS, 2019-2025
24 companies · $2,172 in 2025
The $2,172 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,270 · 2023: $2,722 · 2024: $1,725 · 2025: $2,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,481 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,480.83 |
| Education | $138.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,661.21 | 2022-2025 | |
| Alkermes, INC. | $1,141.91 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $872.07 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $781.00 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $722.01 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $521.49 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $389.53 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $324.81 | 2023-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $264.69 | 2023-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $208.98 | 2022-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $204.98 | 2022 | |
| Corium, LLC | $177.15 | 2023-2025 | Azstarys, Adlarity |
| Tris Pharma INC | $173.31 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| E.R. Squibb & Sons, L.L.C. | $136.42 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $56.52 | 2023-2024 | Adzenys Xr-Odt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $45.67 | 2022-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $38.48 | 2022-2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $35.69 | 2024 | |
| Almatica Pharma LLC | $29.42 | 2022 | |
| Validus Pharmaceuticals LLC | $26.19 | 2024 | Equetro |
| Supernus Pharmaceuticals, INC. | $21.78 | 2023 | Qelbree |
| Collegium Pharmaceutical, INC. | $20.38 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $20.30 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $15.16 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.